Abstract
Aim:
Choice of optimal antihelicobacter (AH) treatment of ulcer.
Materials and methods:
249 outpatients with duodenal ulcer associated with Helicobacter pylori entered a blind multicenter controlled trial. The patients were given one of the following drugs: metronidazole, tonidazol, amoxicilline, clarithromycin, rovamycin, omeprazole, azitromycin.
Results:
Of all the drugs used, rovamycin appeared preferable as it has high AH activity, is safe and cost-effective.
Conclusion:
Rovamycin has a high AH activity and can be applied for treatment of diseases associated with Helicobacter pylori as a drug of choice.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Anti-Bacterial Agents / economics
-
Anti-Bacterial Agents / therapeutic use*
-
Anti-Ulcer Agents / therapeutic use*
-
Cost-Benefit Analysis
-
Drug Therapy, Combination
-
Duodenal Ulcer / drug therapy*
-
Duodenal Ulcer / economics
-
Duodenal Ulcer / microbiology
-
Helicobacter Infections / drug therapy*
-
Helicobacter Infections / economics
-
Helicobacter Infections / microbiology
-
Helicobacter pylori / drug effects
-
Helicobacter pylori / isolation & purification*
-
Humans
-
Intestinal Mucosa / microbiology
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Anti-Ulcer Agents